UK Markets closed

Hutchison China MediTech Limited (HCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
37.51-0.90 (-2.34%)
As of 3:57PM EDT. Market open.
Sign in to post a message.
  • D
    David
    Fantastic reaction to the HK listing. At last with Asian investors omn board we will get a proper valuation like Beigene and Innovent. See ya'll at $2bn in 1 to 2 years time.
  • J
    Jerry
    I love how no one knows about this company but eddy. I have been buying since last year and every month buy more. If this company was based in the U.S with their pipeline, would be valued at 2-4 times what it is now. Raise my cost basis with my newer buys, but still a awesome value here. 2019 will be a big year. 2018 may be the last year it is not on the smart money radar. I hope.
  • J
    Jerry
    With such high volume and 17% gain on Wednesday, I expect some news soon. A approval or some great top line news from their vast pipeline. If a USA company had their Innovation Platform (IP) and Commercial Platform (CP) HCM would be trading at $150. Just look at their pipeline and what is coming the next 1-3 years. Since this is a Chinese company, I value their IP at 6 Billion and their CP at 1 Billion on the conservative side. So very undervalued here even with the 17% gain Wednesday. Great value here on potential massive growth.
  • J
    James
    Looks like we should see a rise on volume. People are starting to see there is no negative side to this secondary.
  • D
    David
    Free Technical & Fundamental Analysis by Expert Stock Market Traders @ https://www.ResearchOTC.com
  • e
    eddy
    Once again this is a great opportunity
  • J
    James
    It looks like a lot of the algorithm selling happened when the secondary offering happened. What the holograms failed to account for though was that this is a sale of ADR's by the Maj shareholder.... Just a sale, not a split..... All it says is that the major shareholder needs cash.
  • D
    David
    CKHH disposal complete, so they now own 49.86%, taking them below 50%. Overhang now gone or going fast. Maybe we can get back to a sensible valuation.....TD values the Company at $38.55/ADS
  • Y
    YANG
    Fruquintinib was approved by cFDA yesterday.
  • M
    Mike
    I wrote this in November when the position was trading at 19.00 but it is till applicable.

    https://seekingalpha.com/instablog/32746315-michael-england/5371294-hcm-riding-wave
    HCM- Riding The Wave - Michael England
    seekingalpha.com
  • D
    David
    Trinity Delta issued an updated research note on Thursday

    https://www.trinitydelta.org/research-notes/timing-is-right-for-a-hong-kong-debut/

    I continue to Buy
  • K
    Kenneth
    Can someone explain to me what this secondary offering is all about? Confused with limited press releases
  • e
    eddy
    Hidden gem with real money supporting it
  • e
    eddy
    Super opportunity to buy
  • e
    eddy
    Great opportunity to buy at $26
  • Y
    YANG
    it is time to buy
  • L
    LucifersCutie
    Just got off the phone with Jordan belfort and he says it’s a buy folks! Loading in now!
  • e
    eddy
    Price should be a lot higher. Great buy!
  • D
    David
    This tells you all you need to know about the Company and its brilliant Management Team. This will be a $25bn mcap Company in the next 5 years in my view

    https://www.standard.co.uk/business/anthony-hilton-the-remarkable-tale-of-chimed-s-growth-a3661656.html
    You could have bought shares in Hutchison China MediTech, or Chi-Med, listed on AIM — and on Nasdaq in the US — for 30p in the aftermath of the financial crash in 2008. When this column drew attention to the company in March they were changing hands
    You could have bought shares in Hutchison China MediTech, or Chi-Med, listed on AIM — and on Nasdaq in the US — for 30p in the aftermath of the financial crash in 2008. When this column drew attention to the company in March they were changing hands
    www.standard.co.uk
  • J
    Jerry
    https://finance.yahoo.com/news/chi-med-announces-phase-iii-070000682.html

    Can't win them all, still valuable for company moving forward. Pipeline vast.
    – Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
    – Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 -- Hutchison China MediTech Limited.
    finance.yahoo.com